Search

Christopher A Verbicky

from Broadalbin, NY
Age ~52
Get Report
Also known as:
Chris A Verbicky, Christoph A Verbicky, Christopher A Vernicky, Kathleen Verbicky, Christoph Y
Phone and address:
992 Ridge Rd, Broadalbin, NY 12025
(518) 842-4522
Connected to:
Benjamin R Verbick, 38Darren R Verbick, 60James M Verbicky, 51Jill M Verbick, 61John W Verbicky, 53Jan H Verbiest, 54Katrien A Verbiest, 50Michelle J Verbik, 47Janet F Verbin, 75Mary F Verbis, 65

Christopher Verbicky Phones & Addresses

  • 992 Ridge Rd, Broadalbin, NY 12025 (518) 842-4522 (518) 842-9211 (518) 882-7073
  • Fort Ann, NY
  • Galway, NY
  • 17 Woodthrush Ct, Ballston Spa, NY 12020 (518) 884-9079
  • Bayside, NY
  • York Beach, ME
  • Washingtonvle, NY
  • 17 Woodthrush Ct, Ballston Spa, NY 12020

Work

Company: Coldstream laboratories, inc. Aug 2010 Position: Director of business development and marketing

Education

Degree: MBA School / High School: University at Albany 2005 to 2011 Specialities: Marketing

Skills

Pharmaceutical Industry • Technology Transfer • Product Development • Cro • Business Development • Gmp • Biotechnology • Project Management • New Business Development • Biopharmaceuticals • Management • Regulatory Affairs • Pharmaceutics • Manufacturing • Fda • Life Sciences • Formulation • Organic Synthesis • Validation • Drug Development • Business Strategy • Business Planning • Process Simulation • Drug Discovery • Clinical Development • Contract Negotiation • Strategic Planning • Organic Chemistry • Sop • Leadership • Medical Devices • R&D • Lifesciences • Cross Functional Team Leadership • Contract Manufacturing • Crm • Oncology • Chemistry • Analytical Chemistry • Chromatography • Commercialization • Business Management • Contract Management • Hplc • Pharmaceutical Development • Process Development • Technical Leadership • Generic Drugs

Industries

Pharmaceuticals

Resumes

Resumes

Christopher Verbicky Photo 1

Managing Director

View page
Location:
992 Ridge Rd, Broadalbin, NY 12025
Industry:
Pharmaceuticals
Work:
Coldstream Laboratories, Inc. since Aug 2010
Director of Business Development and Marketing
Johnson Matthey Pharma Services Feb 2009 - Aug 2010
Manager
AMRI Oct 2007 - Jan 2009
Manager, Business Development
Albany Molecular Research, Inc. and Organichem Aug 2004 - Sep 2007
Manager, Project Management
Albany Molecular Research, Inc. Jun 2000 - Oct 2004
Senior Research Scientist 1, Group Leader, Chemical Development
Education:
University at Albany 2005 - 2011
MBA, Marketing University of New Hampshire 1995 - 1999
Ph.D., Synthetic Organic Chemistry
Skills:
Pharmaceutical Industry
Technology Transfer
Product Development
Cro
Business Development
Gmp
Biotechnology
Project Management
New Business Development
Biopharmaceuticals
Management
Regulatory Affairs
Pharmaceutics
Manufacturing
Fda
Life Sciences
Formulation
Organic Synthesis
Validation
Drug Development
Business Strategy
Business Planning
Process Simulation
Drug Discovery
Clinical Development
Contract Negotiation
Strategic Planning
Organic Chemistry
Sop
Leadership
Medical Devices
R&D
Lifesciences
Cross Functional Team Leadership
Contract Manufacturing
Crm
Oncology
Chemistry
Analytical Chemistry
Chromatography
Commercialization
Business Management
Contract Management
Hplc
Pharmaceutical Development
Process Development
Technical Leadership
Generic Drugs

Publications

Us Patents

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7655630, Feb 2, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/201760
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7659253, Feb 9, 2010
Filed:
Jun 2, 2008
Appl. No.:
12/131923
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7659254, Feb 9, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/201586
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse Resistant Lysine Amphetamine Compounds

View page
US Patent:
7662787, Feb 16, 2010
Filed:
May 7, 2007
Appl. No.:
11/745019
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Rob Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Slingerlands NY, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7662788, Feb 16, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/201866
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7671030, Mar 2, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/201950
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7671031, Mar 2, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/202159
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-Resistant Amphetamine Prodrugs

View page
US Patent:
7674774, Mar 9, 2010
Filed:
Aug 29, 2008
Appl. No.:
12/201982
Inventors:
Travis Mickle - Coralville IA, US
Suma Krishnan - Belvedere CA, US
Barney Bishop - Annandale VA, US
Christopher Lauderback - Blacksburg VA, US
James Scott Moncrief - Christiansburg VA, US
Robert Oberlender - Blacksburg VA, US
Thomas Piccariello - Blacksburg VA, US
Bernhard J. Paul - Lexington MA, US
Christopher A. Verbicky - Broadalbin NY, US
Assignee:
Shire LLC - Florence KY
International Classification:
A61K 38/00
A61K 51/00
A61K 31/785
G01N 33/53
G01N 33/00
US Classification:
514 17, 424 169, 424 7816, 436901, 436111, 514 18, 514 12, 514 2
Abstract:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Control profile
Christopher A Verbicky from Broadalbin, NY, age ~52 Get Report